Economic evaluation of new treatments in the field of glaucoma represents a challenge.
In the absence of a clear epidemiological link between intra-ocular pressure (IOP) and disease progression to blindness, the economic impact of treatments that lower IOP on long-term outcome cannot be estimated.
As an alternative, effectiveness may be expressed as the ability to control IOP over time, making it possible to estimate the cost-effectiveness of therapies.
The objective of this study was to investigate treatment strategies for patients newly diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in Germany and to estimate the impact of new topical therapies on the total cost of treatment.
We performed a retrospective analysis of 200 randomly selected patient charts in 50 ophthalmology practices.
Demographics, diagnoses, IOP and detailed resource utilization over 2 years were collected.
Resources were valued independently from the quantitative data collection, and a standard charge from the perspective of the third party payer, as well as a cost from the societal viewpoint, was determined for each item.
A Markov model was created to calculate total treatment costs with the new therapy.
During the 2 years, 54% of patients had their therapy changed at least once.
Mean total charge and cost per patient were DM 815 and DM 1274, respectively.
Mean IOP at baseline was 31.2 mm at baseline and 18.8 mm after 2 years. (...)
Mots-clés Pascal : Glaucome, Traitement, Chimiothérapie, Antiglaucomateux, Coût, Modèle simulation, Recommandation, Aspect économique, Allemagne, Europe, Homme, Oeil pathologie
Mots-clés Pascal anglais : Glaucoma (eye), Treatment, Chemotherapy, Antiglaucomatous agent, Costs, Simulation model, Recommendation, Economic aspect, Germany, Europe, Human, Eye disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0503287
Code Inist : 002B09J. Création : 19/02/1999.